Bristol-Myers Squibb and Pfizer have agreed to stop a Phase 3 trial of investigation agent apixaban in patients with atrial fibrillation,or irregular heartbeat,who are at risk of blood clots and stroke.An interim analysis showed clear evidence of a clinically significant reduction in stroke and blood clots in AF patients.These patients were considered intolerant of,or unsuitable for,vitamin K antagonist therapy,such as Warfarin,and received apixaban rather than aspirin.The analysis also showed apixaban is as safe as aspirin.
The study was conducted in 36 countries by the Population Health Research Institute,which is affiliated with McMaster University in Hamilton,Ontario and Hamilton Health Sciences.Further analysis of the study and an effort to publish and present the results are ongoing.
Pfizer and Bristol-Myers Squibb have been collaborating on the development and commercialization of apixaban since 2007.Apixaban is an oral anticoagulant discovered by Bristol-Myers Squibb.
Pfizer(PFE),Bristol-Myers Squibb(BMY)
No comments:
Post a Comment